H5N1 Bird Flu in depth.

Overview

H5N1 bird flu is a highly pathogenic avian influenza that occasionally infects humans. Caused by Influenza A virus subtype H5N1 (Orthomyxoviridae), it spreads through close contact with infected poultry or contaminated environments, with very limited human-to-human transmission. Key symptoms: fever, cough, conjunctivitis, and severe pneumonia progressing to respiratory failure. The case fatality rate in confirmed human cases is approximately 50%.

The critical pandemic concern with H5N1 is the possibility of the virus acquiring efficient sustained human-to-human transmission through mutation or genetic reassortment with seasonal influenza viruses. Currently, nearly all human cases result from direct contact with infected animals. H5N1 does not transmit efficiently between people, which limits its current global spread but makes it an urgent pandemic preparedness priority.

In 2024, H5N1 was detected in dairy cattle in the United States for the first time, spreading to more than 200 herds across 13+ states, with dozens of confirmed human cases among farm workers (primarily causing conjunctivitis and mild illness). This represented a dramatic expansion of H5N1's mammalian host range and raised fresh pandemic threat concerns.

History & Origin

H5N1 was first isolated from a goose in Guangdong, China in 1996. In 1997, 18 human cases occurred in Hong Kong — the first confirmed human H5N1 infections — with 6 deaths. Hong Kong authorities culled 1.5 million poultry, halting transmission. The virus re-emerged in 2003 and has caused continuous outbreaks since. It spread via migratory bird routes through Central Asia, Europe, Africa, and eventually the Americas.

Major milestones: 2004 Thailand/Vietnam human deaths sparked first major WHO alarm; 2006 Indonesia became the country with the most human deaths; 2011–2012 H5N1 gain-of-function research controversy (Fouchier and Kawaoka studies demonstrating airborne transmission in ferrets); 2014–2022 massive HPAI outbreaks in poultry globally, including killing or culling over 50 million birds in the US; 2024 novel spread into US dairy cattle and associated farm worker cases.

Transmission

• Animal-to-human (primary route): Direct or close unprotected contact with infected live or dead birds (poultry, waterfowl), their faeces, secretions, or contaminated environments (markets, farms). Also: consumption of raw or undercooked poultry, eggs, or dairy products from infected animals.
• Cattle-to-human: Documented in 2024 US outbreak — farm workers exposed through contact with infected cattle milk, respiratory secretions, or eye exposure to raw milk splashing. Unpasteurised raw milk from infected cattle contains high viral titres.
• Human-to-human: Very rare and non-sustained. Limited household clusters (likely from shared animal exposure) reported in Indonesia, China, and Bangladesh. No sustained community transmission documented. This remains the critical missing step for pandemic onset.
• Environmental persistence: H5N1 virus can persist in contaminated environments, especially in cold conditions. Wild bird faeces are a long-distance dispersal mechanism through migratory flyways.

Symptom Timeline

Incubation period: 2–5 days (up to 17 days reported in some cases). Human H5N1 typically causes severe lower respiratory tract disease.

Diagnosis

• RT-PCR: Gold standard for detection. Samples: nasopharyngeal swab, lower respiratory tract specimens (bronchoalveolar lavage most sensitive in severe disease). Requires H5-specific primers for subtype identification. CDC and WHO reference labs perform confirmatory testing.
• Rapid influenza tests: Poor sensitivity for H5N1; a negative rapid test does NOT rule out H5N1 in a patient with epidemiological exposure and compatible illness.
• Culture and sequencing: Required for full characterisation; BSL-3 laboratory required. Genome sequencing tracks evolution toward pandemic-capable mutations.
• Chest imaging: Rapid bilateral infiltrates progressing to extensive consolidation; ground-glass opacities; pleural effusions. CT more sensitive than chest X-ray in early disease.
• Blood tests: Lymphopaenia (low lymphocytes); elevated CK, LDH; elevated ALT/AST; elevated creatinine in severe disease.

Epidemiological exposure history is critical in H5N1 diagnosis — always ask about contact with birds, poultry, cattle, or live animal markets in the 10 days before symptom onset.

Treatment

• Oseltamivir (Tamiflu): First-line antiviral. Neuraminidase inhibitor. Should be started IMMEDIATELY on clinical suspicion — do not wait for laboratory confirmation. 75 mg twice daily for 5 days; higher doses (150 mg BD) and longer durations used in severe disease. Early treatment significantly reduces mortality.
• Zanamivir (Relenza), Peramivir: Alternative neuraminidase inhibitors for patients who cannot take oral oseltamivir. IV peramivir for critically ill patients.
• Baloxavir marboxil (Xofluza): Cap-dependent endonuclease inhibitor; active against H5N1 in vitro; may be used in combination with oseltamivir for severe disease.
• Supportive critical care: Aggressive oxygen support (high-flow, non-invasive ventilation, mechanical ventilation); prone positioning for ARDS; renal replacement therapy if needed; avoidance of unnecessary corticosteroids (controversial — may worsen outcomes).
• Empiric antibiotics: Secondary bacterial pneumonia common; broad-spectrum antibiotics added empirically in hospitalised patients.

Oseltamivir resistance: some H5N1 strains carry the H275Y mutation conferring oseltamivir resistance. Peramivir or baloxavir should be considered for resistant strains. Resistance testing available in reference laboratories. This information is from WHO guidelines for healthcare professionals only. Never take antiviral medications without a doctor's prescription and supervision.

Prevention & Vaccines

• Pre-pandemic H5N1 vaccine stockpiles: Multiple countries (US, EU) maintain government stockpiles of inactivated H5N1 vaccines that can be rapidly deployed and strain-matched upon pandemic onset. The US BARDA stockpile includes H5N1 vaccine doses for first responders.
• mRNA H5N1 vaccine (Moderna mRNA-1018): In 2024, FDA authorized the first mRNA H5N1 vaccine for individuals at elevated risk (farm workers, veterinarians, poultry workers). Single dose. Addresses the 2024 US dairy cattle situation.
• Personal protective equipment: Farm workers and veterinarians handling poultry or cattle in H5N1-affected areas should wear: N95 respirators, eye protection (goggles or face shield), impermeable gloves and gowns. Avoid touching face; practice strict hand hygiene.
• Avoid raw animal products: Raw or undercooked poultry, eggs, or unpasteurised dairy products in outbreak regions. Pasteurisation inactivates H5N1 in milk.
• Avoid live poultry markets: In countries with HPAI H5N1 activity — particularly live bird markets where direct exposure to infected birds occurs.
• Post-exposure prophylaxis: Oseltamivir 75 mg once daily for 10 days for persons with unprotected exposure to confirmed H5N1-infected animals or humans.
• Antiviral stockpiling: WHO recommends countries stockpile oseltamivir sufficient for 25% of population for pandemic preparedness. Existing seasonal flu vaccines offer little protection against H5N1 due to significant antigenic distance.

Global Impact & Pandemic Risk

H5N1 is widely considered the pathogen with the highest pandemic potential among currently circulating zoonotic viruses. Three factors drive this concern: (1) exceptionally high CFR (~60%) in confirmed human cases; (2) global enzootic spread through wild bird populations across all continents; (3) demonstrated mammalian adaptation (cattle in 2024) and ongoing acquisition of mutations that could facilitate human transmission.

The 2024 US dairy cattle outbreak is unprecedented and concerning. By mid-2024, H5N1 had spread to over 200 dairy herds across 13+ states, with dozens of human cases — predominantly causing conjunctivitis and mild flu-like illness. Genomic analysis confirmed spread is primarily between cattle herds through shared equipment and worker movement, not wild birds. A single farm worker developed a respiratory illness with H5N1, the first US human respiratory case. This mammalian adaptation episode is closely monitored by WHO, CDC, and ECDC.

Global poultry losses to HPAI H5N1 and related subtypes exceeded 100 million birds culled or dead between 2021–2024, causing billions in economic losses and significant disruption to egg and poultry supply chains. The spread to mammals — including cats, foxes, sea lions, polar bears, mink, and dairy cattle — in recent years represents a potentially ominous biological trend toward expanded host range.

History & Major Events

Influenza A(H5N1) was first identified as a cause of human infection in Hong Kong in 1997 — 18 people were infected and 6 died, prompting the slaughter of 1.5 million poultry. It re-emerged in Southeast Asia in 2003, spreading across Asia, Europe, the Middle East, and Africa as a poultry epizootic. Between 2003 and 2024, WHO confirmed 908 human cases in 23 countries with 476 deaths (52% CFR) — making H5N1 the most lethal known influenza virus affecting humans.

In 2024, a new chapter began: H5N1 clade 2.3.4.4b spread into U.S. dairy cattle for the first time, with over 200 herds affected across multiple states. Cow-to-human transmission was confirmed in dozens of US farm workers — mostly mild conjunctivitis and respiratory illness, no human-to-human transmission detected. The dairy cow outbreak raised pandemic preparedness concerns globally.

• 1997: Hong Kong — first human H5N1 infections; 6/18 deaths; mass poultry cull contained outbreak
• 2003–2004: Re-emergence in Asia; poultry outbreaks in Vietnam, Thailand, Cambodia, Indonesia
• 2004–2006: Rapid spread into Europe, Middle East, Africa as migratory birds carried virus westward
• 2006: Indonesia — worst human H5N1 year; 55 deaths; documented family cluster with probable limited human-to-human transmission
• 2021–2024: H5N1 clade 2.3.4.4b becomes dominant globally; unprecedented spread into wild birds, seabirds, marine mammals
• 2024: USA — dairy cattle epizootic; first sustained mammalian agricultural H5N1 outbreak; 58+ farm workers infected (mild cases)

Virology & Pandemic Potential

Influenza A H5N1 is a highly pathogenic avian influenza (HPAI) virus. Its genome consists of eight negative-sense RNA segments encoding key proteins: hemagglutinin (HA, H5 subtype), neuraminidase (NA, N1 subtype), and internal proteins including the polymerase complex (PB2, PB1, PA) and matrix/nucleoprotein. The H5 hemagglutinin binds avian-type α-2,3-linked sialic acid receptors, explaining its poor human-to-human transmission (human upper respiratory tract expresses primarily α-2,6-linked receptors).

Pandemic concern: H5N1 has all the ingredients of a potential pandemic strain except for efficient human-to-human transmission. Should H5N1 acquire this capacity — through mutation or reassortment with a human influenza strain — a pandemic with a case fatality rate orders of magnitude higher than seasonal flu could occur. WHO maintains pre-pandemic H5 vaccines and monitors all human cases under the Global Influenza Surveillance and Response System (GISRS). The US maintains a strategic national stockpile of H5N1 vaccines (pre-pandemic candidate strains). The 2024 US dairy cattle outbreak showed H5N1 can adapt to new mammalian hosts, intensifying pandemic preparedness activities.

Key mutations to watch: PB2 627K (mammalian adaptation); E627K enables replication at 33°C (human upper respiratory temperature). HA mutations enabling α-2,6 sialic acid binding. These mutations have not been detected in circulating H5N1 in 2024 but are monitored in all sequenced samples.

Animal Reservoirs & Transmission Routes

• Wild birds: Waterfowl (ducks, geese, shorebirds) are the natural reservoir; typically asymptomatic carriers who shed virus in feces and respiratory secretions
• Poultry: Chickens, turkeys, and geese develop severe disease; HPAI spreads rapidly through flocks with very high mortality; mass culling is the primary control measure
• Dairy cattle (new 2024): H5N1 clade 2.3.4.4b detected in cow milk at very high titers; spread between herds via contaminated equipment and cattle movement; consumption of raw milk poses human infection risk
• Marine mammals: Mass die-offs in seals, sea lions (especially in South America 2023) and polar bears
• Other mammals: Foxes, otters, mink, cats — infected from eating contaminated birds; mink farm outbreak (Spain, 2022) first documented mammal-to-mammal H5N1 spread
• Human routes: Close contact with infected poultry or contaminated environments; raw/unpasteurized cow milk; no documented sustained human-to-human transmission

Pathophysiology: Why H5N1 Is So Deadly

H5N1 causes unusually severe pulmonary disease in humans due to several factors: it replicates efficiently deep in the lower respiratory tract (alveoli) rather than the upper respiratory tract (like seasonal flu); it triggers an extreme innate immune response — a "cytokine storm" with massive release of IL-6, TNF-α, IFN-γ, and other pro-inflammatory mediators. This uncontrolled immune response causes extensive alveolar damage, ARDS (acute respiratory distress syndrome), and multi-organ failure. H5N1 can also spread beyond the lungs to the brain, liver, and other organs, and has been detected in cerebrospinal fluid in some fatal cases.

• Primary viral pneumonia → ARDS → respiratory failure (commonest cause of death)
• Lymphopenia (low lymphocytes) and elevated transaminases common
• Hyperferritinemia, elevated LDH — markers of cytokine storm severity
• Bacterial secondary pneumonia can complicate recovery
• Neurological manifestations: encephalitis, seizures in severe cases

Treatment & Antiviral Stockpiles

• Oseltamivir (Tamiflu): First-line antiviral for H5N1. Must be started within 48 hours of symptom onset for maximum benefit; even later initiation may reduce severity. Most H5N1 strains are oseltamivir-sensitive. WHO recommends a 5-day course; longer courses sometimes used for severe disease.
• Zanamivir (Relenza): Inhaled neuraminidase inhibitor; alternative to oseltamivir.
• Baloxavir marboxil (Xofluza): Cap-dependent endonuclease inhibitor; active against most H5N1 strains; included in some national stockpiles.
• Pre-pandemic vaccines: Several H5N1 vaccine candidates stockpiled by governments (USA, EU, Japan); activated if pandemic is declared. Moderna is developing an mRNA H5N1 vaccine.
• PPE: Healthcare workers managing H5N1 patients use airborne precautions (N95, gown, gloves, face shield); H5N1 may be transmissible by aerosol based on animal studies.

Country-Specific Information

Frequently Asked Questions

Sources & Citations

H5N1 Clades: Understanding the Naming System

Influenza A viruses are classified by their surface proteins (hemagglutinin H1–H18, neuraminidase N1–N11). H5N1 is further divided into clades based on phylogenetic (evolutionary) analysis of the hemagglutinin gene. Currently 10 major H5 clades (0–9) and many subclades are recognized by WHO. The most concerning current clade is 2.3.4.4b — responsible for the unprecedented 2021–2024 global epizootic in wild birds, poultry, and mammals including the 2024 US dairy cattle outbreak.

Pandemic Preparedness Response

H5N1 pandemic preparedness is a core function of WHO, national health ministries, and the Global Influenza Surveillance and Response System (GISRS). Key preparedness activities include:

• Surveillance: WHO requires immediate reporting of all human H5N1 cases. GISRS laboratory network sequences all H5N1 samples for pandemic-risk mutations. FAO-WOAH (World Organisation for Animal Health) monitors animal outbreaks
• Vaccine development: WHO maintains candidate vaccine viruses (CVVs) for each H5N1 clade; manufacturers can scale up production within 3–6 months of pandemic declaration; US HHS has pre-positioned H5N1 vaccine antigen stockpile (~10 million doses)
• Antiviral stockpiles: WHO recommends countries stockpile oseltamivir for 25% of population; US strategic national stockpile contains 50+ million courses of oseltamivir
• Phase 6 pandemic plan: WHO has a detailed 6-phase pandemic plan that triggers specific international coordination, surveillance escalation, and vaccine production at each phase; current H5N1 situation is assessed as Phase 3 (animal/human infections, no sustained human-to-human spread)
• One Health approach: CDC, USDA, and state agencies coordinate surveillance across human and animal health; "test-and-treat" protocols for farm workers exposed to infected dairy cattle implemented in 2024 US outbreak

Protection for Agricultural Workers

Following the 2024 US dairy cattle H5N1 outbreak, specific guidance for farm workers includes:

• PPE: When working with infected or potentially infected animals: N95 respirator (or higher), safety goggles/face shield, gloves, protective clothing/coveralls, rubber boots
• Raw milk avoidance: Do not drink unpasteurized/raw milk from farms with H5N1-positive cattle. HPAI H5N1 has been detected in raw milk at very high titers; pasteurization inactivates the virus
• Symptom monitoring: Workers on H5N1-affected farms should monitor for fever, respiratory illness, or conjunctivitis for 10 days after last exposure; report symptoms immediately to employer and public health
• Testing: Nasal and conjunctival swabs for H5N1 PCR testing available through state health departments for exposed workers
• Treatment: Oseltamivir (Tamiflu) for post-exposure prophylaxis or early treatment of suspected H5N1 in farm workers; available through state health departments

Related Diseases

Key Terms: H5N1 Bird Flu

• HPAI: Highly Pathogenic Avian Influenza — influenza strains that cause severe disease and high mortality in poultry; includes all H5 and H7 strains that spread systemically in birds
• Clade 2.3.4.4b: The current dominant global H5N1 clade responsible for the 2021-2024 wild bird pandemic and 2024 US dairy cattle outbreak
• Hemagglutinin (HA): The surface protein of influenza viruses that mediates attachment to host cells; the "H" in H5N1; 18 HA subtypes exist
• Neuraminidase (NA): The surface enzyme of influenza viruses that enables viral release from cells; the "N" in H5N1; target of oseltamivir (Tamiflu)
• Cytokine storm: Dysregulated overproduction of inflammatory cytokines that causes widespread tissue damage; major mechanism of H5N1 pathology in the lower respiratory tract
• PB2 627K: A key mammalian adaptation mutation in the polymerase complex of H5N1; enables efficient viral replication at 33°C (human upper respiratory temperature)
• GISRS: Global Influenza Surveillance and Response System — WHO's global network of 144 National Influenza Centres that monitor influenza viruses including H5N1
• Pandemic Phase: WHO's 6-phase classification of pandemic risk; current H5N1 is Phase 3 (animal/human cases, no sustained human-to-human transmission)
• Zoonosis: A disease that can spread from animals to humans; H5N1 is a zoonosis with poultry, wild birds, and now dairy cattle as the primary reservoirs
• Extrinsic incubation period: The time between a mosquito (or in influenza context, animal host) acquiring the virus and becoming infectious; for H5N1 in humans: 2-5 days

More H5N1 Questions

Epidemiology at a Glance: H5N1 Bird Flu

CFR in confirmed cases is not representative of true infection-fatality rate — many mild cases may go undetected, especially in areas with limited laboratory diagnosis.

H5N1 Prevention for Agricultural Workers

• PPE when handling poultry/cattle: N95 respirator (or higher), safety goggles, waterproof gloves, coveralls, rubber boots. Change/disinfect before leaving farm.
• No raw milk: Never drink unpasteurized milk from farms with suspected or confirmed H5N1 in cattle. Pasteurized commercial milk is safe.
• Dead bird protocol: Never handle dead wild birds with bare hands. Use gloves and report mass die-offs of wild birds to agricultural or wildlife authorities.
• Symptom monitoring: Monitor for fever, respiratory symptoms, or conjunctivitis (red eyes) for 10 days after any unprotected exposure to infected birds or cattle.
• Report exposure: If you had unprotected contact with H5N1-confirmed birds/cattle, contact your state health department. Post-exposure oseltamivir prophylaxis may be offered.
• Annual flu vaccination: Get seasonal influenza vaccine annually — reduces risk of co-infection that could enable viral reassortment.
• Cooking: Cook all poultry to 74°C (165°F) internal temperature. Wash hands and surfaces after handling raw poultry.
• Travel precautions: In countries with active H5N1 poultry outbreaks, avoid live bird markets, poultry farms, and contact with wild birds.

H5N1: Pandemic Risk Assessment Q&A